Table 3.
eGFR slope during double-blind treatment using a random coefficient linear mixed-effect model (primary, N=30, and intention-to-treat, N=43, populations)
| Primary Population (N=30) | |||
|---|---|---|---|
| Lademirsen (n=20) | Placebo (n=10) | Difference | |
| LS mean (SEM) eGFR slope ml/min per 1.73 m2 per year | −5 (1.9) | −5 (2.7) | −0 (3.3) |
| 95% CI | −8.7 to −1.1 | −10.2 to 0.8 | −6.9 to 6.5 |
| ITT Population (N=43) | |||
|---|---|---|---|
| Lademirsen (n=29) | Placebo (n=14) | Difference | |
| LS mean (SEM) eGFR slope ml/min per 1.73 m2 per year | −9 (2.1) | −7 (3.1) | −2 (3.8) |
| 95% CI | −13.7 to −5.1 | −13.2 to −0.7 | −10.1 to 5.2 |
CI, confidence interval; ITT, intention to treat; LS, least squares.